MedPath

NX DEVELOPMENT CORP

NX DEVELOPMENT CORP logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:1

Trial Phases

1 Phases

Phase 3:2

Drug Approvals

1

FDA:1

Drug Approvals

GLEOLAN

Approval Date
Mar 4, 2021
FDA

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 3
2 (100.0%)

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

Phase 3
Recruiting
Conditions
Ovarian Cancer
Interventions
Drug: Gleolan
First Posted Date
2023-04-07
Last Posted Date
2024-06-05
Lead Sponsor
NX Development Corp
Target Recruit Count
170
Registration Number
NCT05804370
Locations
🇺🇸

Luminis Health Anne Arundel Medical Center, Annapolis, Maryland, United States

Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma

Phase 3
Completed
Conditions
Meningioma
Interventions
Drug: Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)
First Posted Date
2020-03-12
Last Posted Date
2024-06-18
Lead Sponsor
NX Development Corp
Target Recruit Count
108
Registration Number
NCT04305470
Locations
🇺🇸

Mayo Clinic, Phoenix, Arizona, United States

🇺🇸

University of California San Diego, La Jolla, California, United States

🇺🇸

Keck Hospital of USC, Los Angeles, California, United States

and more 14 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.